In the race to develop effective treatments, the drug company Gilead announced that its drug, remdesivir, has shown promising results--very promising--in compassionate use settings. In addition, the FDA has just granted emergency use authorization for a device that removes certain proteins from the bloodstream, possibly preventing a patient's immune system from overreacting to the virus and damaging vital organs, which is a big problem.